Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine

Yoshiro Fujiwara, Katsuyuki Kiura, Masahiro Tabata, Nagio Takigawa, Katsuyuki Hotta, Shigeki Umemura, Masako Omori, Kenichi Gemba, Hiroshi Ueoka, Mitsune Tanimoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A 60-year-old Japanese man presented to our hospital with a painful left hip. Computed tomography showed a tumor in the left kidney and metastases in the left gluteus maximus muscle and lung. The pathological diagnosis of a biopsy specimen obtained from a metastatic lesion in the left gluteus maximus muscle was sarcomatoid renal cell carcinoma. On admission, his general condition was extremely poor. He was confined to bed because of severe left hip pain and confusion, possibly caused by hypercalcemia. This seriously ill patient suffering from advanced sarcomatoid renal cell carcinoma was treated with single-agent gemcitabine, resulting in symptom relief and a dramatic improvement in his status; all of the tumors had regressed significantly by the 11th dose of gemcitabine. These findings indicate that single-agent gemcitabine is one of the few chemotherapeutic agents effective for palliation in patients with sarcomatoid renal cell carcinoma, even those with poor performance status.

Original languageEnglish
Pages (from-to)431-433
Number of pages3
JournalAnti-Cancer Drugs
Volume19
Issue number4
DOIs
Publication statusPublished - Apr 2008

Fingerprint

gemcitabine
Renal Cell Carcinoma
Hip
Confusion
Muscles
Hypercalcemia
Neoplasms
Tomography
Neoplasm Metastasis
Kidney
Biopsy
Pain
Lung

Keywords

  • Gemcitabine
  • Poor performance status
  • Sarcomatoid renal cell carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. / Fujiwara, Yoshiro; Kiura, Katsuyuki; Tabata, Masahiro; Takigawa, Nagio; Hotta, Katsuyuki; Umemura, Shigeki; Omori, Masako; Gemba, Kenichi; Ueoka, Hiroshi; Tanimoto, Mitsune.

In: Anti-Cancer Drugs, Vol. 19, No. 4, 04.2008, p. 431-433.

Research output: Contribution to journalArticle

Fujiwara, Y, Kiura, K, Tabata, M, Takigawa, N, Hotta, K, Umemura, S, Omori, M, Gemba, K, Ueoka, H & Tanimoto, M 2008, 'Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine', Anti-Cancer Drugs, vol. 19, no. 4, pp. 431-433. https://doi.org/10.1097/CAD.0b013e3282f5d336
Fujiwara, Yoshiro ; Kiura, Katsuyuki ; Tabata, Masahiro ; Takigawa, Nagio ; Hotta, Katsuyuki ; Umemura, Shigeki ; Omori, Masako ; Gemba, Kenichi ; Ueoka, Hiroshi ; Tanimoto, Mitsune. / Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. In: Anti-Cancer Drugs. 2008 ; Vol. 19, No. 4. pp. 431-433.
@article{e8a4a339c64e4ef8b51a3544e010dfe7,
title = "Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine",
abstract = "A 60-year-old Japanese man presented to our hospital with a painful left hip. Computed tomography showed a tumor in the left kidney and metastases in the left gluteus maximus muscle and lung. The pathological diagnosis of a biopsy specimen obtained from a metastatic lesion in the left gluteus maximus muscle was sarcomatoid renal cell carcinoma. On admission, his general condition was extremely poor. He was confined to bed because of severe left hip pain and confusion, possibly caused by hypercalcemia. This seriously ill patient suffering from advanced sarcomatoid renal cell carcinoma was treated with single-agent gemcitabine, resulting in symptom relief and a dramatic improvement in his status; all of the tumors had regressed significantly by the 11th dose of gemcitabine. These findings indicate that single-agent gemcitabine is one of the few chemotherapeutic agents effective for palliation in patients with sarcomatoid renal cell carcinoma, even those with poor performance status.",
keywords = "Gemcitabine, Poor performance status, Sarcomatoid renal cell carcinoma",
author = "Yoshiro Fujiwara and Katsuyuki Kiura and Masahiro Tabata and Nagio Takigawa and Katsuyuki Hotta and Shigeki Umemura and Masako Omori and Kenichi Gemba and Hiroshi Ueoka and Mitsune Tanimoto",
year = "2008",
month = "4",
doi = "10.1097/CAD.0b013e3282f5d336",
language = "English",
volume = "19",
pages = "431--433",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine

AU - Fujiwara, Yoshiro

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Takigawa, Nagio

AU - Hotta, Katsuyuki

AU - Umemura, Shigeki

AU - Omori, Masako

AU - Gemba, Kenichi

AU - Ueoka, Hiroshi

AU - Tanimoto, Mitsune

PY - 2008/4

Y1 - 2008/4

N2 - A 60-year-old Japanese man presented to our hospital with a painful left hip. Computed tomography showed a tumor in the left kidney and metastases in the left gluteus maximus muscle and lung. The pathological diagnosis of a biopsy specimen obtained from a metastatic lesion in the left gluteus maximus muscle was sarcomatoid renal cell carcinoma. On admission, his general condition was extremely poor. He was confined to bed because of severe left hip pain and confusion, possibly caused by hypercalcemia. This seriously ill patient suffering from advanced sarcomatoid renal cell carcinoma was treated with single-agent gemcitabine, resulting in symptom relief and a dramatic improvement in his status; all of the tumors had regressed significantly by the 11th dose of gemcitabine. These findings indicate that single-agent gemcitabine is one of the few chemotherapeutic agents effective for palliation in patients with sarcomatoid renal cell carcinoma, even those with poor performance status.

AB - A 60-year-old Japanese man presented to our hospital with a painful left hip. Computed tomography showed a tumor in the left kidney and metastases in the left gluteus maximus muscle and lung. The pathological diagnosis of a biopsy specimen obtained from a metastatic lesion in the left gluteus maximus muscle was sarcomatoid renal cell carcinoma. On admission, his general condition was extremely poor. He was confined to bed because of severe left hip pain and confusion, possibly caused by hypercalcemia. This seriously ill patient suffering from advanced sarcomatoid renal cell carcinoma was treated with single-agent gemcitabine, resulting in symptom relief and a dramatic improvement in his status; all of the tumors had regressed significantly by the 11th dose of gemcitabine. These findings indicate that single-agent gemcitabine is one of the few chemotherapeutic agents effective for palliation in patients with sarcomatoid renal cell carcinoma, even those with poor performance status.

KW - Gemcitabine

KW - Poor performance status

KW - Sarcomatoid renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=47949086939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47949086939&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e3282f5d336

DO - 10.1097/CAD.0b013e3282f5d336

M3 - Article

C2 - 18454054

AN - SCOPUS:47949086939

VL - 19

SP - 431

EP - 433

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 4

ER -